(2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
|
|
(2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid 속성
- 끓는 점
- 582.6±50.0 °C(Predicted)
- 밀도
- 1.115±0.06 g/cm3(Predicted)
- 산도 계수 (pKa)
- 4?+-.0.23(Predicted)
안전
(2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid C화학적 특성, 용도, 생산
용도
(αR,?γR)?-γ-?[[(1,?1-?Dimethylethoxy)?carbonyl]?amino]?-?α-?methyl-?[1,?1''-?biphenyl]?-?4-?pentanoic Acid is a useful synthetic intermediate.(2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid 준비 용품 및 원자재
원자재
준비 용품
(2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid 공급 업체
글로벌( 62)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Standardpharm Co. Ltd. | 86-714-3992388 |
overseasales1@yongstandards.com | United States | 14332 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19552 | 58 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29800 | 58 |
Hefei Hirisun Pharmatech Co., Ltd | +8615056975894 |
shawn@hirisunpharm.com | CHINA | 9911 | 58 |
Hangzhou Huarong Pharm Co., Ltd. | 571-86758373 +8613588754946 |
sales@huarongpharm.com | CHINA | 3148 | 58 |
China National Standard Pharmaceutical Corporation Limited | +8615391658522 |
overseasales@yongstandards.com | China | 11922 | 58 |
Moxin Chemicals | +86-17320513646 +8617320513646 |
anna@molcoo.com | China | 10000 | 58 |
Amadis Chemical Company Limited | 571-89925085 |
sales@amadischem.com | China | 131957 | 58 |
Shanghai Payne Pharmaceutical Technology Co.Ltd | 021-58123769 18678586262 |
info@paynepharm.com | China | 1354 | 58 |
QUALITY CONTROL SOLUTIONS LTD. | +86-0755-66853366 +86-13670046396 |
export03@qcsrm.com | China | 24342 | 58 |
(2R,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid 관련 검색:
AHU-377(heMicalciuM염) (S)-5-[(바이페닐-4-일)카르보닐]피롤리딘-2-온 LCZ696중급 ((R)-2-비페닐-4-일-1-포밀에틸)카르바마이크산t-부틸에스테르 사쿠비트릴불순물7
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoic acid hydrochloride
(2R,4S)-4-([1,1'-Biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoic acid
(R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoic acid
(2S,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoate
(2S,4R)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid
Valsartan
(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid
(2R,4S)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-aMino-2-Methylpentanoate
LCZ696
Ethyl (2R,4S)-4-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-4-(2,5-dioxopyrrolidin-1-yl)butanoate
(2R,4S)-4-([1,1'-Biphenyl]-4-ylmethyl)-4-(4-ethoxy-4-oxobutanamido)-2-methylbutanoic acid
(R,E)-ethyl 5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpent-2-enoate